证券代码：301108 证券简称：洁雅股份 铜陵洁雅生物科技股份有限公司 2023 年度网上业绩说明会投资者关系活动记录表 编号：2024-003 特定对象调研 分析师会议 投资者关系活动 □媒体采访 业绩说明会 类别 □新闻发布会 □路演活动 现场参观 其他 参与单位名称及 洁雅股份 2023 年度业绩说明会采用网络远程方式进行，面向全体 人员姓名 投资者。 时间 2024年4月30 日 15:00-17:00 地点 全景网“投资者关系互动平台”（http://rs.p5w.net） 董事长、总经理：蔡英传先生； 董事、财务总监：杨凡龙先生； 上市公司接待人 独立董事：何文龙先生； 员姓名 副总经理、董事会秘书：胡能华先生； 保荐代表人：章付才先生。 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 129,636,863.19, representing a 1.43% increase compared to CNY 127,803,768.87 in the same period last year[5] - Net profit attributable to shareholders decreased by 62.70% to CNY 13,901,683.51 from CNY 37,270,675.22 year-on-year[5] - The net profit after deducting non-recurring gains and losses fell by 74.94% to CNY 7,996,116.36 compared to CNY 31,911,553.02 in the previous year[5] - Basic and diluted earnings per share decreased by 63.04% to CNY 0.17 from CNY 0.46 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 129,636,863.19, an increase of 1.4% compared to CNY 127,803,768.87 in Q1 2023[18] - Net profit for Q1 2024 decreased to CNY 13,872,350.05, down 62.7% from CNY 37,262,970.59 in Q1 2023[19] - Earnings per share for Q1 2024 was CNY 0.17, compared to CNY 0.46 in the same period last year[20] Cash Flow and Liquidity - Operating cash flow increased by 20.49% to CNY 24,938,524.30 from CNY 20,696,967.09 in the same period last year[5] - Cash received from the sale of goods increased by 34.47% to CNY 206,866,555.77, attributed to higher sales volume[9] - The net cash flow from operating activities for Q1 2024 was ¥24,938,524.30, an increase of 20.8% compared to ¥20,696,967.09 in Q1 2023[23] - Total cash inflow from investment activities reached ¥643,734,635.32, significantly up from ¥350,882,667.79 in the same period last year[23] - The net cash flow from investment activities was ¥20,610,864.36, a recovery from a negative cash flow of -¥245,469,814.02 in Q1 2023[23] - The company reported a net increase in cash and cash equivalents of ¥47,029,018.60, contrasting with a decrease of -¥223,897,592.82 in Q1 2023[23] - The total cash and cash equivalents at the end of Q1 2024 stood at ¥687,848,487.06, compared to ¥762,938,886.06 at the end of Q1 2023[23] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 2,133,717,437.33, a decrease of 0.70% from CNY 2,148,772,775.84 at the end of the previous year[5] - The total current assets amount to ¥1,613,013,856.60, showing a slight increase from ¥1,587,545,952.99[15] - The accounts receivable decreased to ¥123,940,902.76 from ¥170,879,336.43, a reduction of approximately 27.5%[14] - The inventory increased to ¥72,325,287.98 from ¥68,925,743.74, representing a growth of about 6.5%[15] - The company's long-term equity investments rose to ¥24,792,868.88 from ¥15,719,954.06, an increase of approximately 57.5%[15] - The total liabilities decreased to CNY 258,984,894.91 from CNY 289,820,192.75 year-over-year[19] - The total liabilities include accounts payable of ¥103,627,743.40, down from ¥123,619,841.80, a decrease of about 16.2%[15] Expenses - The company's sales expenses rose by 69.06% to CNY 2,550,541.47, mainly due to increased consulting fees[9] - Total operating costs rose significantly to CNY 124,185,235.77, up 32.1% from CNY 93,994,590.15 in the previous year[18] - Research and development expenses for Q1 2024 were CNY 5,275,852.08, slightly up from CNY 5,090,366.20 in Q1 2023[19] - Cash paid for purchasing goods and services was ¥149,275,706.49, up from ¥105,310,040.71 in the previous year, indicating a 41.8% increase[23] - Cash paid to employees was ¥22,734,352.15, an increase from ¥19,333,036.45, reflecting a growth of 12.4%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,407, with no preferred shareholders having restored voting rights[11] - The largest shareholder, Cai Yingchuan, holds 52.88% of the shares, totaling 42,946,052 shares[11] - The company has no preferred shareholders or significant changes in restricted shares during the reporting period[13] Future Outlook - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[19] Accounting and Reporting - The company has not yet adopted the new accounting standards as of the first quarter of 2024[24] - The first quarter report was not audited[24]

证券代码：301108 证券简称：洁雅股份 公告编号：2024-040 铜陵洁雅生物科技股份有限公司 第五届监事会第十七次会议决议公告 一、监事会会议召开情况 铜陵洁雅生物科技股份有限公司（以下简称"公司"）第五届监事会第十七 次会议于 2024 年 4 月 25 日以现场结合通讯方式召开。会议通知于 2024 年 4 月 20 日以电子邮件方式发出。本次监事会应出席监事 3 人，实际出席监事 3 人（其 中监事俞彦诚先生以通讯表决的方式出席）。会议由公司监事会主席卢云凤女士 主持。本次监事会会议的召开符合《中华人民共和国公司法》等有关法律、行政 法规、部门规章、规范性文件及《公司章程》的规定。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 二、监事会会议审议情况 经与会监事认真审议，形成如下决议： 1、审议通过《关于<公司 2024 年第一季度报告>的议案》 经审议，公司监事会认为：公司《2024 年第一季度报告》真实反映了公司 2024 年第一季度的财务状况和经营成果，符合法律、行政法规、中国证监会和 深圳证券交易所的相关规定，报告内容真实、准确，完整， ...

证券代码：301108 证券简称：洁雅股份 公告编号：2024-042 铜陵洁雅生物科技股份有限公司 关于注销部分募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 因开展募集资金现金管理的需要，根据《上市公司监管指引第 2 号—上市公 司募集资金管理和使用的监管要求》的相关规定，铜陵洁雅生物科技股份有限公 司（以下简称"公司"）在中国农业银行股份有限公司铜陵高新区支行开立了现 金管理专用结算账户，专用于募集资金购买理财产品的结算，不得用于存放非募 集资金或用作其他用途。具体内容详见公司于 2024 年 2 月 8 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于开立闲置募集资金现金管理专用结算账户的 公告》（公告编号：2024-012）。 铜陵洁雅生物科技股份有限公司董事会 2024 年 4 月 25 日 鉴于上述专用结算账户相关的理财产品已全部赎回且无后续使用计划，账户 内资金已全部转回募集资金专项账户。为规范账户管理，根据《上市公司监管指 引第 2 号—上市公司募集资金管理和使用的监管要求》、《深圳证券交 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301108 证券简称：洁雅股份 公告编号：2024-039 铜陵洁雅生物科技股份有限公司 第五届董事会第十九次会议决议公告 一、董事会会议召开情况 铜陵洁雅生物科技股份有限公司（以下简称"公司"）第五届董事会第十九 次会议于 2024 年 4 月 25 日以现场结合通讯方式召开，本次会议的通知已于 2024 年 4 月 20 日通过电子邮件的方式送达全体董事。本次会议应出席董事 9 人，实 际出席董事 9 人（其中独立董事何文龙、赵波、陈彦以通讯表决的方式出席）。 本次会议由董事长兼总经理蔡英传先生主持，公司监事及高级管理人员列席本次 会议。本次董事会会议的召开符合《中华人民共和国公司法》等有关法律、行政 法规、部门规章、规范性文件及《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 1、审议通过《关于<公司 2024 年第一季度报告>的议案》 经审议，公司董事会认为：公司《2024 年第一季度报告》真实反映了公司 2024 年第一季度的财务状况和经营成果，符合法律、行政 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% compared to the Shanghai Composite Index within the next six months [11][13]. Core Insights - In 2023, the company reported a revenue of 622.59 million yuan, a year-on-year decline of 6.60%, primarily due to a 57.01% drop in the medical and antibacterial wet wipes segment. The net profit attributable to the parent company was 115.20 million yuan, down 18.28% year-on-year [1][6][14]. - The company is focusing on its core wet wipes business while expanding into the beauty and cosmetics sector, with a new R&D center in Shanghai and partnerships to enhance its product offerings [2][16]. - The company expects revenue growth in the coming years, projecting revenues of 669.2 million yuan in 2024, 754.65 million yuan in 2025, and 856.3 million yuan in 2026, alongside net profits of 114 million yuan, 130 million yuan, and 149 million yuan respectively [6][16]. Financial Summary - The company's gross margin for 2023 was 29.62%, a decrease of 1.84 percentage points year-on-year, while the net profit margin was 18.4%, down 2.75 percentage points [1][14]. - The sales expense ratio increased to 1.55%, up 0.48 percentage points year-on-year, and the management expense ratio rose to 7.8%, up 2.52 percentage points, mainly due to increased consulting fees and stock-based compensation [1][14]. - The company’s wet wipes product revenue was 524 million yuan, a decline of 10.90%, while the face mask segment saw a revenue increase of 15.65% to 66.55 million yuan [15][24]. Business Segmentation - The wet wipes segment remains the core business, with a focus on recovering orders for disinfectant wipes. The company is also diversifying into the beauty sector, which is expected to contribute to future growth [15][16]. - The production capacity utilization rates for wet wipes, face masks, and personal care products were 69.04%, 95.09%, and 9.84% respectively, indicating room for improvement in the personal care segment [15][16].

铜陵洁雅生物科技股份有限公司 募集资金管理制度 第一章 总则 第一条 为进一步规范铜陵洁雅生物科技股份有限公司（以下简称"公司"） 募集资金的管理和运用，提高募集资金使用效率，保护投资者合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》等有关法律、法规及有关规范性文件及《铜陵洁雅生物科技股份有限公司章 程》（下称"《公司章程》"）的有关规定，结合公司实际情况，制定本制度。 第二条 本制度所称"募集资金"是指公司通过向不特定对象发行证券或者 向特定对象发行证券（包括股票、可转换公司债券等）募集并用于特定用途的资 金，但不包括公司实施股权激励计划募集的资金。 第三条 募集资金只能用于公司对外公布的募集资金投资项目，公司董事会 应制定详细的资金使用计划。募集资金的使用应坚持周密计划、规范运作、公开 透明的原则，并按相关规定及时披露募集资金使用情况。 第四条 非经公司股东大会依法作出决议，不得变更公司公告的募集资金投 向 ...

l | | RSM 容 诚 募集资金年度存放与使用情况鉴证报告 容诚专字|2024|230Z0449 号 容诚会计师事务所(特殊普通合伙) 中国 北京 铜陵洁雅生物科技股份有限公司 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台《http://w.cn.pc.gw.cn】"进行企 。 | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 募集资金年度存放与使用情况鉴证报告 | 1-3 | | 2 | 募集资金年度存放与使用情况专项报告 | 4-7 | 目 录 er 募集资金年度存放与使用情况鉴证报告 按照中国证券监督管理委员会《上市公司监管指引第 2 号 -- 上市公司募集 资金管理和使用的监管要求》、深圳证券交易所《深圳证券交易所上市公司自律监 管指引第 2 号 -- 创业板上市公司规范运作》及《深圳证券交易所创业板上市公 司自律监管指南第 2 号 -- 公告格式》的规定编制《关于募集资金年度存放与使 用情况的专项报告》是洁雅股份董事会的责任.这种责任包括保证其内容真实、准 确、完整,不存在虚假记录、误导性陈述或重大遗漏。 三、注册会计师的责任 我们的责任是对洁雅 ...

RSM 容诚 内部控制鉴证报告 铜陵洁雅生物科技股份有限公司 容诚专字[2024]230Z0450 号 容诚会计师事务所(特殊普通合伙) 中国 · 北京 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acconf.exn.com.com.com.com.com.com.com.com.com.cn. 目 录 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 内部控制鉴证报告 | | 1-3 | | 2 | 内部控制自我评价报告 | | 4-12 | 内部控制鉴证报告 容诚专字[2024]230Z0450 号 铜陵洁雅生物科技股份有限公司全体股东: 我们鉴证了后附的铜陵洁雅生物科技股份有限公司(以下简称洁雅股份)董事 会编制的 2023年12月 31 日与财务报告相关的内部控制有效性的评价报告。 一、对报告使用者和使用目的的限定 本鉴证报告仅供洁雅股份年度报告披露之目的使用,不得用作任何其他目的。 我们同意将本鉴证报告作为洁雅股份年度报告必备的文件,随其他文件一起报送 并对外披露。 二、企业对内部控制的责任 四、工作概述 我们按照《 ...

Financial Performance - The company's operating revenue for 2023 was ¥622,587,051.34, a decrease of 6.60% compared to ¥666,562,814.54 in 2022[19]. - The net profit attributable to shareholders for 2023 was ¥115,196,493.09, down 18.28% from ¥140,965,003.50 in 2022[19]. - The net profit after deducting non-recurring gains and losses was ¥88,906,482.39, a decline of 31.35% from ¥129,512,124.15 in 2022[19]. - The net cash flow from operating activities was ¥83,514,114.39, a significant drop of 72.07% compared to ¥299,015,628.70 in 2022[19]. - The total assets at the end of 2023 amounted to ¥2,148,772,775.84, reflecting a 3.96% increase from ¥2,066,863,492.46 at the end of 2022[19]. - The net assets attributable to shareholders increased by 4.47% to ¥1,858,648,481.97 at the end of 2023, compared to ¥1,779,133,963.66 at the end of 2022[19]. - The company reported a basic earnings per share of ¥1.42 for 2023, down 18.39% from ¥1.74 in 2022[19]. - The weighted average return on equity for 2023 was 6.35%, a decrease of 1.79% from 8.14% in 2022[19]. - The gross profit margin for the reporting period was 29.62%, down by 1.85 percentage points year-on-year[50]. - The company reported a total revenue of 2,600,000,000 CNY for the year, with a year-on-year growth rate of 52.0%[78]. - The net profit for the period was -532,917,840 CNY, indicating a significant loss compared to the previous year[78]. Dividend Distribution - The company plans to distribute a cash dividend of 3.6 RMB per 10 shares to all shareholders, based on a total of 81,209,818 shares[3]. - The company implemented a cash dividend policy, distributing 5.00 CNY per 10 shares (before tax) to shareholders, totaling 29,210,334.48 CNY in cash dividends[164]. - The cash dividend total accounted for 100% of the total profit distribution amount[165]. Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings through new technologies and research[3]. - The wet wipes market in China is projected to grow from ¥116 billion in 2023 to ¥146 billion by 2028, indicating significant growth potential in the industry[31]. - The company is pursuing a "two verticals and one horizontal" strategy to enhance market expansion and innovation efforts[48]. - The company aims to expand its product line to include a variety of cleaning and disinfecting wipes, catering to diverse consumer needs[61]. - The company is actively investing in upstream raw material supply stability by participating in the equity of related companies[48]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of $G million set aside for this purpose[117]. Research and Development - The company has a stable core technical team with 6 invention patents and 46 utility model patents in the wet wipes product technology field, providing a strong foundation for product development[40]. - The company has established a research and development center for personal care products in Shanghai, indicating a strategic expansion into the personal care market[40]. - The company invested CNY 22,519,611.41 in R&D in 2023, accounting for 3.62% of its operating revenue, a slight decrease from 3.79% in 2022[64]. - Research and development expenses decreased by 10.96% to ¥22,519,611.41, attributed to reduced investment in R&D[60]. - The company is focusing on developing environmentally friendly multi-functional wipes with enhanced antibacterial and moisturizing capabilities[64]. - The company is investing 100 million CNY in R&D for new technologies aimed at enhancing product efficiency[196]. Risk Management - The company faces risks related to raw material price fluctuations, as direct materials constitute a significant portion of its cost structure, potentially impacting profitability[105]. - The company has a high customer concentration risk, relying heavily on major clients like Woolworths and Johnson & Johnson, which could affect revenue if these clients change their procurement strategies[106]. - The company is exposed to exchange rate fluctuations, particularly as its export trade is primarily settled in USD, which could impact financial performance[109]. - The company’s risk management includes measures to address potential risks such as exchange rate volatility and customer default risks[83]. Corporate Governance - The company emphasizes the importance of accurate financial reporting and has confirmed that all board members attended the meeting to review the annual report[3]. - The company’s board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[123]. - The company conducted 7 board meetings and 6 supervisory board meetings during the reporting period, adhering strictly to relevant laws and regulations[124]. - The company maintains complete independence from its controlling shareholder in terms of assets, personnel, finance, organization, and business operations[126]. - The company has established a strong governance structure, ensuring compliance and accountability within its operations[136]. Environmental and Social Responsibility - The company has achieved ISO 14001:2015 environmental management system certification, demonstrating commitment to environmental standards[183]. - The company has implemented energy-saving measures, including the use of LED lights and smart control systems, to reduce carbon emissions[182]. - The company promotes a safety-first approach in production, ensuring employee safety and environmental protection[185]. - The company has committed to legal operations and supports local economic development through tax compliance[185]. - The company has not faced any environmental penalties during the reporting period, reflecting compliance with environmental regulations[182]. Employee Management - The company has established a three-dimensional salary distribution mechanism based on job value, technical ability, and work performance[161]. - The total remuneration for directors, supervisors, and senior management in 2023 amounted to 4.6022 million yuan[149]. - The company has a total of 706 employees receiving salaries, including 8 retired employees[159]. - The company is committed to building a learning organization and has established a comprehensive employee training management system[162]. Future Outlook - The company provided guidance for the next quarter, expecting revenue to be between $A million and $B million, indicating a growth rate of C%[117]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[145]. - The company aims to achieve a revenue growth target of 10% in the upcoming fiscal year[136]. - The company has set a revenue guidance of 1.5 billion CNY for the next fiscal year, indicating a growth target of 25%[198].